IL6 targeting is also used in the treatment of GVHD; JA2 inhibition is used in the treatment of acute GVHD and this represents inhibition of JAK2-STAT3 signaling that is the main intracellular pathway downstream to the IL6Rα-gp130 receptor [113,114,115]. This evidence concerns the gene IL6 and acute graft versus host disease.